Lead Product(s) : Ibandronate Sodium,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Ibandronate Sodium Tablets 150 mg Under Fasting Condition
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 26, 2012
Lead Product(s) : Ibandronate Sodium,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ibandronate Sodium,Inapplicable
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Sponsor : Taisho Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Transfer and Future Marketing of Osteoporosis Agent Bonviva in Japan
Details : Bonviva is a medicine that contains the active substance ibandronic acid. It is available as tablets (150 mg) and as a solution for injection in a prefilled syringe (3 mg).
Product Name : Bonviva
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 24, 2022
Lead Product(s) : Ibandronate Sodium,Inapplicable
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Sponsor : Taisho Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ibandronate Sodium,Inapplicable
Therapeutic Area : Musculoskeletal
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study To Assess The Quality Of Bone In Patients Taking Oral Ibandronate Versus Placebo
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 31, 2016
Lead Product(s) : Ibandronate Sodium,Inapplicable
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ibandronate Sodium,Inapplicable
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable
Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 15, 2016
Lead Product(s) : Ibandronate Sodium,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ibandronate Sodium,Inapplicable
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 23, 2016
Lead Product(s) : Ibandronate Sodium,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ibandronate Sodium,Inapplicable
Therapeutic Area : Musculoskeletal
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 13, 2015
Lead Product(s) : Ibandronate Sodium,Inapplicable
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ibandronate Sodium,Inapplicable
Therapeutic Area : Musculoskeletal
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 06, 2015
Lead Product(s) : Ibandronate Sodium,Inapplicable
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alendronate Sodium,Ibandronate Sodium
Therapeutic Area : Musculoskeletal
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 05, 2015
Lead Product(s) : Alendronate Sodium,Ibandronate Sodium
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ibandronate Sodium,Inapplicable
Therapeutic Area : Musculoskeletal
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 05, 2015
Lead Product(s) : Ibandronate Sodium,Inapplicable
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ibandronate Sodium,Inapplicable
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Ibandronate (Bondronat) in Participants With Metastatic Bone Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 30, 2015
Lead Product(s) : Ibandronate Sodium,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
